rLP2086
Sponsors
Pfizer
Conditions
HealthyMeningitisMeningitis, Meningococcal, Serogroup BMeningococcal VaccineMeningococcal VaccinesN Meningitidis Serogroup BRepevaxVaccines
Phase 2
Study Evaluating Safety & Immunogenicity of rLP2086 Vaccine in Adolescents
CompletedNCT00387725
Start: 2006-11-30End: 2008-02-29Updated: 2014-11-21
A Trial to Assess the Safety, Tolerability and Immunogenicity of Repevax and rLP2086 Vaccine When Given Together in Healthy Subjects Aged >=11 to <19 Years.
CompletedNCT01323270
Start: 2011-03-18End: 2013-02-19Updated: 2022-10-27
A Clinical Trial to Study the Safety, Tolerance and Immunogenic Response to Gardasil and Bivalent rLP2086 Vaccine When Given at the Same Time to Children Between the Ages of 11 and 17
CompletedNCT01461993
Start: 2011-09-28End: 2013-07-06Updated: 2018-12-19
Study To Describe The Safety, Tolerability, And Immunogenicity Of Bivalent Rlp2086 Vaccine In Laboratory Workers ≥18 To ≤65 Years Of Age
CompletedNCT01768117
Start: 2013-02-28End: 2014-02-28Updated: 2018-12-20
Phase 3
A Trial to Assess the Safety, Tolerability, and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Young Adults Aged >=18 to <26 Years.
CompletedNCT01352845
Start: 2013-05-31End: 2015-02-28Updated: 2016-02-23
A Trial to Assess the Lot Consistency, Safety, Tolerability and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Subjects Aged ≥10 to <19 Years
CompletedNCT01830855
Start: 2013-04-30End: 2015-04-30Updated: 2016-06-14
A Trial to Describe the Immunogenicity and Safety of 2 Doses of Bivalent rLP2086 (Trumenba) and a Pentavalent Meningococcal Vaccine in Healthy Subjects >=10 to <26 Years of Age.
CompletedNCT03135834
Start: 2017-04-24End: 2022-10-25Updated: 2023-08-08